To speculate, our results might suggest that increased β2‐AR signalling contributes to the immune suppressing effects of VEGF in melanoma, and sensitises tumour cells to the efficacy of specific VEGF‐A blockade by bevacizumab. The gene discussed is ADRB2; the disease is melanoma.